Insider Selling: Sera Prognostics (NASDAQ:SERA) CEO Sells 20,139 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,139 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total transaction of $40,278.00. Following the completion of the transaction, the chief executive officer directly owned 844,870 shares in the company, valued at $1,689,740. This trade represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Performance

NASDAQ SERA traded down $0.01 during trading hours on Wednesday, hitting $2.00. The company had a trading volume of 8,250 shares, compared to its average volume of 49,384. The business has a 50 day moving average of $2.05 and a 200-day moving average of $2.02. The company has a market cap of $78.90 million, a PE ratio of -2.99 and a beta of 0.98. Sera Prognostics, Inc. has a 1-year low of $1.56 and a 1-year high of $3.95.

Sera Prognostics (NASDAQ:SERA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.07 million. Sera Prognostics had a negative net margin of 47,475.72% and a negative return on equity of 46.71%. Sell-side analysts expect that Sera Prognostics, Inc. will post -0.62 earnings per share for the current fiscal year.

Institutional Trading of Sera Prognostics

A number of institutional investors have recently added to or reduced their stakes in SERA. Arkadios Wealth Advisors purchased a new position in Sera Prognostics in the first quarter valued at about $25,000. Lido Advisors LLC purchased a new stake in shares of Sera Prognostics during the 3rd quarter worth approximately $68,000. Cetera Investment Advisers acquired a new stake in shares of Sera Prognostics in the 4th quarter worth approximately $74,000. Qube Research & Technologies Ltd acquired a new stake in shares of Sera Prognostics in the 2nd quarter worth approximately $92,000. Finally, Two Sigma Investments LP purchased a new position in Sera Prognostics in the 3rd quarter valued at approximately $97,000. Hedge funds and other institutional investors own 54.64% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Craig Hallum started coverage on shares of Sera Prognostics in a research note on Thursday, June 4th. They set a “buy” rating and a $6.00 target price for the company. Weiss Ratings lowered Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $5.50.

Sera Prognostics Company Profile

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.